All lobbying filings

AVIVA STRATEGIES (FKA MGB CONSULTING)

Lobbying for ULTRAGENYX PHARMACEUTICAL · Biopharma company

Filing Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 15, 2026

Income

$38,000.00

What the client paid this registrant for the period.

Client based in

California

Official filing document

Government bodies contacted 3

Food & Drug Administration (FDA)
HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

- ultrarare disease - newborn screening - pediatric priority review voucher

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.